Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Cell-mediated Immune Responses01:40

Cell-mediated Immune Responses

Overview
Special Features of Adaptive Immunity01:20

Special Features of Adaptive Immunity

The adaptive immune system, a crucial component of the overall immune response, offers a highly specialized defense against pathogens. It involves specific cell types and features, enabling it to combat infections effectively and efficiently.
The primary cell types involved in adaptive immunity are T cells and B cells. Each type has a unique role in defending the body against pathogens. T cells are responsible for cell-mediated immunity. They identify and eliminate infected cells directly,...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term survivors of melanoma after anti-PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Publisher Correction: CLEAR-IT, a framework for contrastive learning to capture the immune composition of tumor microenvironments.

Communications biology·2026
Same author

Blood-based kinase activity profiling to predict response to immune checkpoint inhibitors in patients with advanced stage NSCLC: the prospective IOpener study.

Journal for immunotherapy of cancer·2026
Same author

In Remembrance of Professor Zelig Eshhar: <i>A Life Committed to CAR-T</i>.

Human gene therapy·2026
Same author

A roadmap for supporting the development of advanced therapy medicinal products in a European framework.

The Lancet regional health. Europe·2026
Same author

Molecular profile of residual triple-negative breast cancer: opportunities for post-neoadjuvant therapeutic interventions.

NPJ breast cancer·2026

Related Experiment Video

Updated: May 10, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Genetically modified T lymphocytes: more than just direct effectors.

Cor H J Lamers1, Reno Debets

  • 1Laboratory of Experimental Tumor Immunology, Department of Medical Oncology, Erasmus MC Cancer Institute, PO Box 5201, 3008 AE Rotterdam, The Netherlands. c.lamers@erasmusmc.nl

Immunotherapy
|July 9, 2013
PubMed
Summary

Genetically modified T lymphocytes targeting MAGE-A3 antigen showed clinical benefit in melanoma patients. Patients developing MAGE-A3-specific immune responses experienced improved outcomes, highlighting cellular vaccine potential.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice
09:08

Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice

Published on: July 11, 2016

Related Experiment Videos

Last Updated: May 10, 2026

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates
06:10

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice
09:08

Retroviral Transduction of Bone Marrow Progenitor Cells to Generate T-cell Receptor Retrogenic Mice

Published on: July 11, 2016

Area of Science:

  • Immunology
  • Oncology
  • Cellular Therapy

Background:

  • T lymphocytes are crucial for antigen-specific immune responses against cancer.
  • Cancer-testis antigens like MAGE-A3 are targets for cancer immunotherapy.
  • Genetically modified T cells offer a novel approach for cancer vaccination.

Purpose of the Study:

  • To evaluate the clinical and immunological responses in melanoma patients vaccinated with MAGE-A3-genetically modified T lymphocytes.
  • To explore the immunogenicity and therapeutic potential of T cells engineered to express MAGE-A3.
  • To correlate MAGE-A3-specific immune responses with clinical benefit in melanoma.

Main Methods:

  • Twenty-three patients with MAGE-A3-expressing melanoma were treated with MAGE-A3-transduced T cells.
  • Immune responses were monitored for MAGE-A3 specificity.
  • Clinical benefit was assessed in relation to immune responses.

Main Results:

  • Six out of twenty-three patients developed MAGE-A3-specific immune responses.
  • Patients with MAGE-A3-specific immune responses demonstrated clinical benefit.
  • Patients lacking MAGE-A3-specific immune responses did not show clinical benefit.

Conclusions:

  • Vaccination with MAGE-A3-genetically modified T cells can induce antigen-specific immune responses in melanoma patients.
  • The development of MAGE-A3-specific immunity correlates with clinical benefit, suggesting efficacy of this cellular vaccine approach.
  • Genetically modified T cells hold promise as a therapeutic strategy for MAGE-A3-expressing cancers.